Business

Carey Turnbull Wears Many Hats as a Donor and Investor

The founder of two leading psychedelic science companies and an influential nonprofit is shaping research, as well as efforts to patent it. 

What’s the Future of Eleusis Therapeutics After Acquisition by Beckley Psytech?

Eleusis’ IV form of psilocin will see clinical trials, but Eleusis-backed research into the anti-inflammatory properties of psychedelics is uncertain.

Eleusis Holdings Plans To Be Acquired By Beckley Psytech

The acquisition is the latest sign of stress among startups in the sector, which has seen valuations plummet.

Young Psychedelic Philanthropist Blazes Path for the Psychedelic Future

With the support of his family, Cody Swift has funded pivotal research into psychedelic therapies and the conservation of peyote and other Indigenous medicines. 

Can Psychedelics Treat Inflammation and Eye Disease? Eleusis Thinks So.

The company is betting that psychedelic medicines can promote physical as well as mental health. Can it convince investors?

Journey Colab Looks to Mescaline for Treating Alcohol Use Disorder

An early advocate of indigenous reciprocity, the company seeks more funding to support FDA clinical trials.

Numinus’s Acquisition of Novamind May Signal More Consolidation to Come

Payton Nyquvest, Numinus’s CEO, sees the company’s move into the U.S. as a step towards “a global clinic network.”

A New Database Seeks to Prevent “Bad” Psychedelic Patents

Porta Sophia is building an online database of prior art pertaining to psychedelics with the goal of improving the flawed psychedelic patent process.

Funders at Johns Hopkins Shape The Future of Psychedelic Research

Partnerships between funders and researchers at Johns Hopkins illustrate how companies influence the direction of psychedelic science and the release of research data to the public domain.

These Natural Psilocybin Droplets Come in Exact Dosages and Don’t Upset Your Stomach

Mimosa Therapeutics has created a cultured psilocybin mycelium product called Pearls that can be precisely dosed like synthetic psilocybin, but contains all the mushroom’s compounds.